IPO Application! In the next two weeks, the pharmaceutical stock will strike

According to the IPO arrangement, 8 new shares will be applied for in A-shares in the next two weeks (November 14-27), including one pharmaceutical stock, namely Jiangsu Dongxing Intelligent Medical Technology Co.
, Ltd.
(hereinafter referred to as "Dongxing Medical"
).
On November 10, Dongxing Medical issued shares for the first time and listed on the Growth Enterprise Market (GEM) announced that the application date of this offline issuance was the same as the online application date on November 21, with a total of 25,043,334 shares, accounting for no less than 25% of the total share capital after the issuance, all of which were new shares
.
Among them, 6.
386 million shares were issued online, with an application limit of 06,000 shares, and the market value of Dingge application was 60,000 yuan
.
According to the data, Dongxing Medical, formerly known as Jiangsu Dongxing Medical Equipment Co.
, Ltd.
, was successfully listed on the New Third Board in December 2015 and terminated its listing
on November 20, 2020.
On June 30, 2021, the company submitted a prospectus on the Growth Enterprise Market and was accepted, and it was approved by the listing committee meeting on May 12
, 2022.
At present, the company is actively planning and promoting the initial public offering and listing on the Growth Enterprise Market
.
Dongxing Medical is a domestic medical device enterprise, which has four business segments
: surgical agent equipment, surgical instrument R & D and production, surgical equipment parts R & D and production and surgical equipment R & D and production.
It is understood that after the company was listed on the new third board market, it was keen to acquire, and successively included Suzhou Sanfeng Original Medical Technology Co.
, Ltd.
, Changzhou Wick Medical Equipment Co.
, Ltd.
and Jiangsu Zihang Precision Hardware Co.
, Ltd.
, which also completed the transformation from a single business and sales enterprise to a comprehensive enterprise integrating production, research and development, and sales, realizing the closed-loop of the industrial chain and the construction
of a new business model 。 According to the prospectus, Dongxing Medical is mainly engaged in the research and development, production and sales of surgical medical devices represented by stapler, and has realized the whole industrial chain layout from stapler product development, mold development, parts production, product assembly to downstream sales
.
Among them, the revenue contribution of the stapler category accounts for about 40% to 50%.

At present, the domestic medical device industry has entered the era of innovation, and increasing R&D investment is crucial
for enterprises to enhance their innovation capabilities and core competitiveness.
Dongxing Medical has also always attached great importance to scientific research investment, focused on R&D innovation, and continued to reap results
.
As of June 30, 2022, Dongxing Medical has obtained 43 medical device registration certificates and filing certificates, including 3 Class I and 40 Class II medical device products
.
As of the same period, the company has obtained a total of 155 patents, including 23 invention patents
.
According to the financial report data, in 2019, 2020, 2021 and the first half of 2022, the revenue of Dongxing Medical reached 296 million yuan, 374 million yuan, 446 million yuan and 212 million yuan, the net profit reached 48.
2376 million yuan, 80.
2756 million yuan, 111 million yuan and 52.
2753 million yuan respectively, and the net profit after deduction reached 44.
9457 million yuan, 73.
5692 million yuan, 103 million yuan and 49.
5502 million yuan respectively
。 In addition, the company expects to achieve revenue of 322 million yuan ~ 345 million yuan in the first three quarters of this year, a year-on-year increase of 4.
65% ~ 12.
13%; The net profit is expected to be 79 million yuan to 82.
7 million yuan, a year-on-year increase of 9.
80%~14.
94%; It is expected that the non-net profit will be 74.
8 million yuan ~ 78.
2 million yuan, a year-on-year increase of 9.
72% ~ 14.
71%.

It is reported that the company intends to raise 613 million yuan this time, and the funds raised will be used for the intelligent manufacturing and expansion project of Zihang medical device parts, the new product project of minimally invasive surgery of Wake Medical and the project of medical surgical equipment research and development center
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.